Shares of Zealand Pharma experienced a significant surge, jumping 16% as the market opened on Monday, following the release of groundbreaking phase II trial results for an experimental obesity treatment being developed in collaboration with Boehringer Ingelheim. This surge came as the trial testing the drug survodutide for the treatment of fatty liver, specifically metabolic